IP Library Granted Patent US 9,718,786
Granted Patent B2
US 9,718,786 · App. 14/845,320 · Granted Aug 1, 2017

Contrast agents for myocardial perfusion imaging

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,718,786
App. No.
14/845,320
Granted
Aug 1, 2017
Kind
B2
Abstract

The present disclosure is directed, in part, to compounds and methods for imaging myocardial perfusion, comprising administering to a patient a contrast agent which comprises a compound that binds MC-1, and an imaging moiety, and scanning the patient using diagnostic imaging.

Claims (28)

1. A method for synthesizing a compound, comprising:

reacting a precursor species having the following structure,

wherein R 3 is C 1-6 alkyl substituted with a hydroxyl group, alkoxy substituted with a hydroxyl group, or alkoxyalkyl substituted with a hydroxyl group, in the presence of p-toluenesulfonyl chloride, to produce a compound having the following structure,

wherein R 4 is C 1-6 alkyl substituted with a tosyl group, alkoxy substituted with a tosyl group, or alkoxyalkyl substituted with a tosyl group.

2. The method of claim 1 , further comprising:

reacting the compound in the presence of a 18 F-containing species to produce a contrast agent comprising 18 F.

3. The method of claim 1 , wherein the precursor species has the following structure,

4. The method of claim 1 , wherein the compound has the following structure,

5. The method of claim 1 , further comprising:

reacting a species having the following structure,

wherein R 2 is C 1-6 alkyl substituted with a protected hydroxyl group, alkoxy substituted with a protected hydroxyl group, or alkoxyalkyl substituted with protected hydroxyl group, the protected hydroxyl group comprising a trialkylsilyl group, in the presence of tetraalkylammonium fluoride, to produce the precursor species.

6. The method of claim 5 , wherein the species has the following structure,

7. The method of claim 5 , further comprising:

reacting, via an etherification reaction, a heterocyclic species having the following structure,

wherein R 1 is chloro or a hydroxyl group, with a substituted phenyl species having the following structure,

wherein R 2 is C 1-6 alkyl substituted with a protected hydroxyl group, alkoxy substituted with a protected hydroxyl group, or alkoxyalkyl substituted with a protected hydroxyl group, the protected hydroxyl group comprising a trialkylsilyl group.

8. The method of claim 7 , wherein the heterocyclic species has the following structure,

9. The method of claim 7 , wherein the substituted phenyl species has the following structure,

10. A method for synthesizing a contrast agent, comprising:

reacting a compound having the following structure,

wherein R 4 is C 1-6 alkyl substituted with a tosyl group, alkoxy substituted with a tosyl group, or alkoxyalkyl substituted with a tosyl group, in the presence of a 18 F-containing species to produce a contrast agent comprising 18 F.

11. A method for synthesizing a contrast agent, comprising:

reacting a precursor compound having the structure:

in the presence of a 18 F-containing species to produce a contrast agent comprising the structure:

12. The method of claim 11 , wherein the precursor compound is formed via reaction of p-toluenesulfonyl chloride with a hydroxyl-containing compound comprising the structure:

13. The method of claim 12 , wherein the hydroxyl-containing compound is formed via reaction of tetraalkylammonium fluoride with a species comprising the structure:

14. The method of claim 13 , wherein the species is formed via reaction with a heterocyclic species comprising the structure:

with a substituted phenyl species comprising the structure:

Assignments (9)
RELEASE OF SECURITY INTEREST Recorded Jun 27, 2019
From: JPMORGAN CHASE BANK, N.A.
To: LANTHEUS MEDICAL IMAGING, INC.
Reel/Frame 049623/0123 →
PARTIAL RELEASE OF SECURITY INTEREST Recorded Apr 26, 2017
From: JPMORGAN CHASE BANK, N.A.
To: LANTHEUS MEDICAL IMAGING, INC.
Reel/Frame 042336/0384 →
SECURITY AGREEMENT Recorded Mar 31, 2017
From: LANTHEUS MEDICAL IMAGING, INC.
To: JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT
Reel/Frame 042118/0986 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 12, 2015
From: CASEBIER, DAVID S.; ROBINSON, SIMON P.; PUROHIT, AJAY; RADEKE, HEIKE S.; AZURE, MICHAEL T.; DISCHINO, DOUGLAS D.
To: BRISTOL-MYERS SQUIBB PHARMA COMPANY
Reel/Frame 037019/0675 →
MERGER Recorded Nov 12, 2015
From: ACP LANTERN ACQUISITION, INC.
To: BRISTOL-MYERS SQUIBB MEDICAL IMAGING, INC.
Reel/Frame 037019/0687 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 12, 2015
From: BRISTOL-MYERS SQUIBB PHARMA COMPANY
To: ACP LANTERN ACQUISITION, INC.
Reel/Frame 037099/0300 →
CHANGE OF NAME Recorded Nov 12, 2015
From: BRISTOL-MYERS SQUIBB MEDICAL IMAGING, INC.
To: LANTHEUS MEDICAL IMAGING, INC.
Reel/Frame 037099/0361 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 12, 2015
From: CASEBIER, DAVID S.; ROBINSON, SIMON P.; PUROHIT, AJAY; RADEKE, HEIKE S.; AZURE, MICHAEL T.; DISCHINO, DOUGLAS D.
To: BRISTOL-MYERS SQUIBB COMPANY
Reel/Frame 037019/0653 →
NUNC PRO TUNC ASSIGNMENT Recorded Nov 12, 2015
From: BRISTOL-MYERS SQUIBB COMPANY
To: BRISTOL-MYERS SQUIBB PHARMA COMPANY
Reel/Frame 037019/0663 →